Iovance Biotherapeutics Reports Third-Quarter Revenue of $121.47 Million
Third-quarter revenue increased 80% year over year, while net loss narrowed 76%. Higher Amtagvi infusions, corresponding Proleukin sales and price increases drove revenue growth; lower R&D spending and the absence of prior-year restructuring charges contributed to the narrower loss.
Iovance Biotherapeutics’ third-quarter revenue increased 80% year over year, while its net loss narrowed 76%. Higher Amtagvi infusions, corresponding Proleukin sales and price increases for both products drove revenue growth; lower R&D spending and the absence of prior-year restructuring charges al…